Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Kintor Pharmaceutical Ltd ( (HK:9939) ) just unveiled an update.
Kintor Pharmaceutical Ltd reported a significant increase in revenue to RMB6.0 million for the first half of 2025, driven by global sales of its KOSHINÉ cosmetics brand. Despite this growth, the company experienced a net loss increase due to higher R&D and marketing costs, reflecting its strategic focus on advancing clinical trials for its dermatology pipelines. The company is implementing measures such as the Top-up Placing 2025 to support ongoing R&D efforts, although no interim dividend will be paid for this period.
More about Kintor Pharmaceutical Ltd
Kintor Pharmaceutical Ltd is a company incorporated in the Cayman Islands, primarily engaged in the pharmaceutical industry. The company focuses on the development and commercialization of dermatology products, with a notable emphasis on its high-end cosmetics brand KOSHINÉ and core dermatology pipelines KX-826 and GT20029.
Average Trading Volume: 6,878,171
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.06B
For detailed information about 9939 stock, go to TipRanks’ Stock Analysis page.